Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Pharmaceutical
A New Drug Application filing with the US Food and Drug Administration for ITCA 650 as treatment of type 2 diabetes (T2D) has been submitted. 21 November 2016
Pharmaceutical
Recognizing the crucial need for early screening to detect type 2 diabetes and manage the risk of its serious complications, 'Eyes on Diabetes' is this year’s theme for World Diabetes Day which fell on November 14, 2016. 15 November 2016
Pharmaceutical
With the coming of the 25th“World Diabetes Day,” R&D Based Pharmaceutical Association Committee of China Association of Enterprises with Foreign Investment (RDPAC) released Faces of Innovation: Meeting the Challenge of Diabetes today in Beijing. 14 November 2016
Biosimilars
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended four new medicines and three biosimilars for approval at its November meeting. 12 November 2016
Pharmaceutical
Results from a comparative pharmacodynamics study have shown the potential benefits of Tresiba (insulin degludec) over a rival in patients with type 1 diabetes. 12 November 2016
Pharmaceutical
Two US lawmakers sent a letter last Thursday to the Justice Department and the Federal Trade Commission asking them to investigate potential collusion or anticompetitive behavior among pharmaceutical companies that manufacture diabetes products in setting their drug prices. 5 November 2016
Biosimilars
The European Medicines Agency (EMA) has accepted for review Mylan’s regulatory submission its version of diabetes treatment insulin glargine, referencing Lantus, the original product from France’s Sanofi. 4 November 2016
Pharmaceutical
German pharma major Merck KGaA has inaugurated its 170 million euros ($189 million) Nantong pharmaceutical plant in China at the same time as announcing a further 80 million euros investment in a life sciences center nearby. 4 November 2016
Pharmaceutical
French pharma major Sanofi’s shares were up 7.7% before market opening, after it lifted its profit guidance for the full-year 2016 and detailing news of a big share buyback. 28 October 2016
Pharmaceutical
Novo Nordisk today post financial results, showing that net profit for the third quarter of 2016 increased 16.9% to 9.8 billion Danish kroner ($1.44 billion). 28 October 2016
Pharmaceutical
Novo Nordisk has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration and a Type II Variation application to the European Medicines Agency. 26 October 2016
Pharmaceutical
AstraZeneca has granted Chinese biotech firm 3SBio an exclusive license to commercialize type 2 diabetes drugs Byetta (exenatide) and the once-weekly version, Bydureon, In China. 13 October 2016
Pharmaceutical
Aetna, one of the USA's leading diversified health care benefits companies, has entered into a value-based agreement with pharma giant Merck & Co for the type 2 diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin plus metformin). 12 October 2016
Pharmaceutical
The German Institute for Quality and Efficiency in Health Care (IQWiG) has reassessed whether AstraZeneca’s Onglyza (saxagliptin) and the combination drug Komboglyze (saxagliptin and metformin) have advantages or javascript:void(0);disadvantages in comparison with the appropriate comparator therapies for the patients. 11 October 2016
Pharmaceutical
Danish diabetes care giant Novo Nordisk revealed on Friday that it has received a Complete Response Letter from the US Food and Drug Administration regarding the New Drug Application for faster-acting insulin aspart. 8 October 2016
Pharmaceutical
The National Institute for Health and Care Excellence (NICE) today published final draft guidance recommending Forxiga (dapagliflozin) for treating type 2 diabetes in ‘triple therapy’. 7 October 2016
Biotechnology
Metabrain Research has signed an agreement with Medicxi, a European life sciences venture capital firm, for the inception of Kymo Therapeutics, incorporated in Cambridge, UK. 7 October 2016
Pharmaceutical
Around 1,000 jobs are to go at Danish diabetes giant Novo Nordisk, which amounts to nearly 2.4% of its total global workforce.
This action has been described in a statement as “one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market.” 29 September 2016
Biotechnology
Nordic biotech firm Swedish Orphan Biovitrum has appointed Milan Zdravkovic its new head of research and development (R&D). 27 September 2016
Pharmaceutical
Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to grow, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development, according to results of a new study conducted by the Tufts Center for the Study of Drug Development. 21 September 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze